Search for a trial

Melanoma, artificial reproductive therapy and pregnancy; is there an increased risk of recurrence?

The aim of this study is to evaluate if a recurrent melanoma is more common after ART or pregnancy after a previous history of stage I or II melanoma. Other forms of hormonal therapy will be examined. Also, anxiety about pregnancy or hormonal…

Longitudinal analysis of tumor-specific T-cel immunity in irresectable stage IIIc and stage IV melanoma patients

• To study the effect of treatment (e.g. anti-CTLA4, BRAF inhibition, TIL therapy) on the size and diversity of melanoma-specific T cell populations as measured by MHC tetramer technology and antigen-specific cytokine production. • To examine…

An open, multicentre, randomised, inter-individual comparative, prospective clinical trial with MD-3511356 versus standard sun protection measures in immunosuppressed outpatients after solid organ transplantations for the prevention of UV-induced infections and carcinogenic skin alterations

3. TRIAL OBJECTIVES AND PURPOSE3.1 Primary ObjectiveThe primary objective is the prevention of actinic keratoses and squamous cell carcinomas by local application of MD-3511356 in comparison to standard sun protection measures in immuno-suppressed…

Quality of life of patients with actinic keratoses and/or a superficial basal cell carcinoma treated with 5% Imiquimod cream.

To evaluate patient related outcomes mainly quality of life and treatment satisfaction. Side effects and therapy adherence were also evaluated because these can interfere with quality of life and treatment satisfaction.

Donor leukapheresis for T-cell receptor gene therapy for treatment of metastatic melanoma (skin cancer)

Collecting T cells of 2 stage IV melanoma patients via leucapheresis for conducting test runs in order to develop a gene therapy study.

Integrated analyses of melanoma-T cell interactions; relevance for immunotherapy

Our purpose is to establish whether the frequently observed absence of tumor regression in the presence of infiltrating T lymphocytes is due to a lack of T cell effector function or due to an inhibitory influence of the tumor microenvironment on T…

Isolation, immortalization and characterization of human B lymphocytes for the development of diagnostic and therapeutic antibodies against cancer.

Until recently, the field of anti-tumor immunology has focussed on the role of T lymphocytes. Recently, however, the group of prof. H. Spits and dr. T. Beaumont developed an in vitro methodology to grow human, monoclonal, B cell receptor positive…

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB (RO5185426) ADJUVANT THERAPY IN PATIENTS WITH SURGICALLY RESECTED, CUTANEOUS BRAF-MUTANT MELANOMA AT HIGH RISK FOR RECURRENCE

Primary ObjectiveThe primary objective of this study is as follows:* To evaluate the efficacy of vemurafenib adjuvant treatment administered over a 52-week period in patients with completely resected BRAFV600 mutation*positive, cutaneous melanoma,…

Patient reported outcomes in high risk and advanced melanoma patients

Primary outcome is to assess HRQoL in high risk and advanced melanoma patients treated with immune checkpoint-inhibitors. Secondary outcomes are to describe anxiety and depression; fear of cancer recurrence; melanoma-specific HRQoL; symptoms and…

Quality of life research among melanoma patients that have been treated with immunotherapy, or targeted therapy and/or surgery

This study will evaluate Health-Related Quality of Life (general and disease specific), socio-demographic data, anxiety, depression, fear for cancer recurrence, immunotherapy related discomforts, sexual health, social functioning (work ability),…

A Multicenter, Randomized, Double blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome

Primary Objective:To assess the number of new BCCs in the 2 arms (Patidegib Topical Gel, 2%, and Vehicle (placebo)) when applied twice daily to the face of subjects with Gorlin Syndrome.Secondary Objective:To assess the safety and tolerability of…

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group.

This study has been transitioned to CTIS with ID 2023-509136-25-00 check the CTIS register for the current data. To prospectively assess whether post-operative adjuvant therapy with pembrolizumab improves recurrence-free survival (RFS) as compared…